A combined approach for the early detection of ovarian cancer in asymptomatic women

https://doi.org/10.1016/0301-2115(95)02369-0Get rights and content

Abstract

The purpose of this study was to investigate the effectiveness of the combined procedure including pelvic examination and serum CA-125 determination, as a screening method for the early detection of ovarian cancer. In 2000 women over 45 years old, without any evidence of adnexal disease, pelvic examination and serum CA-125 determination were performed. When either the findings of the pelvic examination were ambiguous or positive, or the serum CA-125 level was > 35 U/ml, further investigation including ultrasonography and laparoscopy or laparotomy was done. Among 174 women with clinical findings of adnexal disease there were 15 (8.62%) who had serum CA-125 > 35 U/ml. Among 18 women with elevated serum CA-125 (> 35 U/ml) there were 15 women (83.33%) who had clinical findings of adnexal disease. In 15 women further investigation was suggestive of adnexal disease and surgical exploration revealed three cases of malignancy. One case of serious ovarian cystadenocarcinoma stage Ia, one case of borderline ovarian tumour and one case of metastatic carcinoma from the right kidney. The other 12 women had benign adnexal masses or pelvic endometriosis. In our study this combined approach had sensitivity 100%, specificity 99.70% and P.P.V. 22%. According to these data, the procedure could be a potential component of a strategy aimed to the early detection of ovarian cancer, regardless of the financial cost.

References (14)

There are more references available in the full text version of this article.

Cited by (65)

  • Pelvic exam in gynecology and obstetrics: Guidelines for clinical practice

    2023, Gynecologie Obstetrique Fertilite et Senologie
  • N<sup>o</sup> 385 - Indications de l'examen pelvien

    2019, Journal of Obstetrics and Gynaecology Canada
    Citation Excerpt :

    La revue a aussi examiné l'essai QUEST (Quality of Life, Education, and Screening Trial), un essai clinique randomisé de moindre envergure qui ne faisait rapport que sur les effets psychologiques33. La section sur le dépistage du cancer de l'ovaire du rapport sur les éléments probants de l'USPSTF de 201710 et l’énoncé de recommandations11 sur l'examen pelvien de dépistage des maladies gynécologiques chez les femmes asymptomatiques à risque moyen citaient les mêmes études en plus de 3 petites études de cohorte prospectives non randomisées publiées il y a plus de 20 ans48-50. La directive clinique de 2014 de l'ACP sur l'examen pelvien de dépistage, cautionnée par le GECSSP en 20169, citait seulement l'essai PLCO pour justifier ses recommandations sur le dépistage du cancer de l'ovaire8.

  • No. 385-Indications for Pelvic Examination

    2019, Journal of Obstetrics and Gynaecology Canada
    Citation Excerpt :

    They also evaluated the Quality of Life, Education, and Screening Trial (QUEST), a smaller, randomized controlled trial that only reported psychological outcomes.33 The section on ovarian cancer screening in the USPSTF's 2017 evidence report10 and recommendation statement11 on screening pelvic examination for gynaecologic diseases in asymptomatic, average-risk women cited the same studies with the addition of 3 small, nonrandomized prospective cohort studies published over 20 years ago.48–50 The 2014 ACP guideline on screening pelvic examination, which was endorsed by the CTFPHC in 2016,9 cited only the PLCO trial in justifying its recommendations regarding ovarian cancer screening.8

  • A systematic review of the bimanual examination as a test for ovarian cancer

    2015, American Journal of Preventive Medicine
    Citation Excerpt :

    Study characteristics are summarized in Table 1 and Appendix Table 1. Three of the screening studies enrolled women at high risk for ovarian cancer based on their family history or the presence of a BRCA mutation,22–24 whereas the other five studies predominantly enrolled postmenopausal asymptomatic women at average risk for ovarian cancer.17–21 All of the studies with symptomatic women enrolled those scheduled for exploratory laparotomy for adnexal mass of unknown origin.

  • Theranostic nanostructures for ovarian cancer

    2019, Critical Reviews in Therapeutic Drug Carrier Systems
View all citing articles on Scopus
View full text